EMEA Statement On Valdecoxib (Bextra/Valdyn) & Parecoxib Sodium (Dynastat/Rayzon)

"The European Medicines Agency (EMEA) and its Scientific Committee for human medicines have been made aware of new safety information on cardiovascular and serious skin adverse events in relation to the use of valdecoxib and parecoxib sodium." [Medical News Today]